Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis.
Conclusions: Compared with other SU-lowering treatments, febuxostat does not increase or decrease the risk of cardiovascular disease but may increase the risk of CVD death. More RCTs measuring cardiovascular safety as a primary outcome are needed to adequately evaluate the risk of CVD with febuxostat.
PMID: 30863448 [PubMed]
Source: International Journal of Rheumatology - Category: Rheumatology Tags: Int J Rheumatol Source Type: research
More News: Allopurinol | Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Gout | Heart | Rheumatology | Study | USA Health | Warnings